PL424035A1 - Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową - Google Patents

Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową

Info

Publication number
PL424035A1
PL424035A1 PL424035A PL42403516A PL424035A1 PL 424035 A1 PL424035 A1 PL 424035A1 PL 424035 A PL424035 A PL 424035A PL 42403516 A PL42403516 A PL 42403516A PL 424035 A1 PL424035 A1 PL 424035A1
Authority
PL
Poland
Prior art keywords
dendritic cells
tumor
immune response
optimally activated
tumor immune
Prior art date
Application number
PL424035A
Other languages
English (en)
Polish (pl)
Inventor
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL424035A1 publication Critical patent/PL424035A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL424035A 2015-06-30 2016-06-29 Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową PL424035A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187086P 2015-06-30 2015-06-30
PCT/US2016/040134 WO2017004230A1 (en) 2015-06-30 2016-06-29 Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

Publications (1)

Publication Number Publication Date
PL424035A1 true PL424035A1 (pl) 2019-01-02

Family

ID=57609106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424035A PL424035A1 (pl) 2015-06-30 2016-06-29 Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową

Country Status (14)

Country Link
US (2) US11124768B2 (https=)
EP (2) EP3317403B1 (https=)
JP (3) JP6985939B2 (https=)
KR (1) KR102763373B1 (https=)
CN (2) CN114774356A (https=)
AR (1) AR106496A1 (https=)
AU (2) AU2016286112B2 (https=)
CA (1) CA2990640A1 (https=)
ES (1) ES3032055T3 (https=)
IL (2) IL256522B2 (https=)
MX (2) MX2018000056A (https=)
PL (1) PL424035A1 (https=)
RU (1) RU2018103235A (https=)
WO (1) WO2017004230A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
SG11202011806WA (en) 2018-06-21 2021-01-28 Univ Gent Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
JP2022552200A (ja) * 2019-10-07 2022-12-15 ノースウエスト バイオセラピューティクス，インコーポレイティド 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法
CN119286782B (zh) * 2024-12-11 2025-04-04 上海赛笠百傲生物医药有限公司 一种高效诱导外周血来源单核细胞至不成熟树突状细胞的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040203143A1 (en) * 2003-02-27 2004-10-14 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
JP2015107133A (ja) * 2001-09-06 2015-06-11 ノースウエスト バイオセラピューティクス，インコーポレイティド 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CN1713951B (zh) 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
KR100887560B1 (ko) 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
CA2704232C (en) * 2007-11-08 2017-05-02 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
ES2686708T3 (es) 2008-04-18 2018-10-19 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
US10238723B2 (en) * 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015107133A (ja) * 2001-09-06 2015-06-11 ノースウエスト バイオセラピューティクス，インコーポレイティド 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法
US20040203143A1 (en) * 2003-02-27 2004-10-14 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. SALLUSTO ET AL: "1994", "EFFICIENT PRESENTATION OF SOLUBLE ANTIGEN BY CULTURED HUMAN DENDRITIC CELLS IS MAINTAINED BY GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR PLUS INTERLEUKIN 4 AND DOWNREGULATED BY TUMOR NECROSIS FACTOR ALFA" J. EXP. MED. 1994, 179 *
M.B. LUTZ ET AL: "2000", "IMMATURE DENDRITIC CELLS GENERATED WITH LOW DOSES OF GM-CSF IN THE ABSENCE OF IL-4 ARE MATURATION RESISTANT AND PROLONG ALLOGRAFT SURVIVAL IN VIVO" EUR. J. IMMUNOL., 2000, 30 *

Also Published As

Publication number Publication date
AR106496A1 (es) 2018-01-24
RU2018103235A (ru) 2019-07-31
US20220145246A1 (en) 2022-05-12
IL256522B1 (en) 2024-06-01
JP2024101059A (ja) 2024-07-26
WO2017004230A1 (en) 2017-01-05
EP3317403B1 (en) 2025-03-05
IL256522B2 (en) 2024-10-01
BR112017028602A2 (pt) 2018-09-04
ES3032055T3 (en) 2025-07-15
CN107849537A (zh) 2018-03-27
MX2023001622A (es) 2023-03-09
CA2990640A1 (en) 2017-01-05
EP4574159A2 (en) 2025-06-25
AU2023202977A1 (en) 2023-06-01
RU2018103235A3 (https=) 2019-12-23
AU2023202977B2 (en) 2026-03-05
IL256522A (en) 2018-02-28
AU2016286112A1 (en) 2018-02-15
EP4574159A3 (en) 2025-09-17
JP2022023248A (ja) 2022-02-07
KR102763373B1 (ko) 2025-02-07
EP3317403A1 (en) 2018-05-09
AU2016286112B2 (en) 2023-02-16
MX2018000056A (es) 2018-05-28
JP6985939B2 (ja) 2021-12-22
HK1255084A1 (en) 2019-08-02
JP2018523996A (ja) 2018-08-30
IL312668A (en) 2024-07-01
US11124768B2 (en) 2021-09-21
US20180187145A1 (en) 2018-07-05
EP3317403A4 (en) 2019-07-03
CN114774356A (zh) 2022-07-22
KR20180022949A (ko) 2018-03-06

Similar Documents

Publication Publication Date Title
PL424035A1 (pl) Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
DK1567155T3 (da) Administration of dendritiske celler, der er delvist modnet in vitro til behandlingen af tumorer
RU2018145512A (ru) Биологические маркеры, которые могут быть использованы в иммунотерапии рака
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
EA201690016A1 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2019008419A (es) Métodos de fabricación de harinas de nueces y formulaciones para inmunoterapia oral.
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
MX2023006546A (es) Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.
EP4219690A3 (en) Methods of cancer treatment using activated t cells
EP4495133A3 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
AR107278A1 (es) Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
MX2018002017A (es) Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
MX2024006240A (es) Vacunas contra el metapneumovirus humano.
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
MY192216A (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
MX2021001914A (es) Peptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celulas no peque?as (nsclc).
DK3229831T3 (da) Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer
EA201892518A1 (ru) ЗАМЕЩЕННЫЕ 5,6,7,8-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИН-3(2H)-ОН И 2,5,6,7-ТЕТРАГИДРО-3H-ПИРРОЛО[2,1-c][1,2,4]ТРИАЗОЛ-3-ОН И ИХ ПРИМЕНЕНИЕ